A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients
Why the study?
Does enoxaparin 40 mg subcutaneously per day reduce the risk of venous thromboembolism in patients with acute medical illnesses compared to placebo?
Population
Patients with acute medical illnesses
Comparison
Enoxaparin 40 mg subcutaneously per day vs Placebo
Design
RCT
Authors
Discussion
Loading...
Member takes
Implication
Supports enoxaparin 40 mg daily for VTE prophylaxis in acute medical illness; confirms LMWH efficacy versus placebo in this population.
Structured PICO
Does enoxaparin 40 mg subcutaneously per day reduce the risk of venous thromboembolism in patients with acute medical illnesses compared to placebo?
P
Population
Patients with acute medical illnesses
I
Intervention
Enoxaparin 40 mg subcutaneously per day
C
Comparator
Placebo
O
Outcome
Venous thromboembolismhard clinical
Enoxaparin 40 mg daily is safe and effective for VTE prophylaxis in acutely ill medical patients.
Cite This Study
Samama et al. (1999) studied this question.